Brainstorm Cell Therapeutics Inc.
BCLI
$0.69
$0.00-0.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.32% | 23.77% | 10.18% | 28.63% | 32.39% |
| Total Depreciation and Amortization | -17.08% | -19.37% | -16.99% | -12.98% | -9.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 668.78% | -78.86% | -62.37% | -78.99% | -93.67% |
| Change in Net Operating Assets | -30.69% | 145.30% | 114.04% | 130.67% | 129.47% |
| Cash from Operations | 23.29% | 35.72% | 34.35% | 60.78% | 55.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -93.88% | -93.48% | -93.62% | -99.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -45.42% | -47.32% | -70.66% | -66.57% | -58.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -13.64% | -30.24% | -60.57% | -53.44% | -58.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.47% | 87.06% | -184.56% | 181.60% | -256.24% |